Alpha-2 Plasmin Inhibitor, Plasma
Synonyms |
|
||||||||
Cerner Name |
|||||||||
Clinical Info |
Diagnosing congenital alpha-2 plasmin inhibitor deficiencies (rare) Providing a more complete assessment of disseminated intravascular coagulation, intravascular coagulation and fibrinolysis, or hyperfibrinolysis (primary fibrinolysis), when measured in conjunction with fibrinogen, fibrin D-dimer, fibrin degradation products, soluble fibrin monomer complex, and plasminogen Evaluating liver disease Evaluating the effects of fibrinolytic or antifibrinolytic therapy |
||||||||
Specimen Sources |
Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous |
||||||||
Specimen Types |
Blood |
||||||||
Specimen Volume |
|||||||||
Container |
Blue Top Tube |
||||||||
Collection Instructions |
See Coagulation Studies in Special Instructions: Guidelines for |
||||||||
Transport Instructions |
|||||||||
Specimen Stability |
|||||||||
Methodology |
Chromogenic |
||||||||
Days Performed |
Monday through |
||||||||
Performing Laboratory |
Mayo Medical Laboratories |
||||||||
CPT |
85410; LOINC Code: 27810-1; |
||||||||
PDM |
5601205 |
||||||||
Only Orderable at Locations: |
Orderable Everywhere |
||||||||
Results |
|
||||||||
Result Interpretation
Adults: 80-140%
Normal, full-term newborn infants may have borderline low or mildly decreased levels (≥50%) which reach adult levels within 5 to 7 days postnatal.* Healthy, premature infants (30-36 weeks gestation) may have mildly d |
|||||||||
Forms |
|